About: Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Sector: Healthcare
Industry: Biotechnology
Latest price: $37.54 (+3.30%)
XENE NASDAQ Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc share price
Atividade de preço de XENE
Último preço
$ 37,540
Variação (24h)
1,20 USD (3,30%)
Volume
1.54M
Volume (média 4 sem.)
-
Abertura
$ 37,27
Variação do dia
$ 36,49 - $ 37,69
Fechamento anterior
$ 36,34
Último negócio
29 Oct, 8:28 pm GMT+0
Atrasado
29 Oct, 8:28 pm GMT+0
XENE price performance
Atrasado
29 Oct, 8:28 pm GMT+0
quote.marketSignals